A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Ewing's sarcoma; Osteosarcoma
- Focus Therapeutic Use
- 25 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2018 According to an Exelixis media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress.
- 31 Aug 2018 Biomarkers information updated